UNSPSC 51342307: Penciclovir

This classification denotes a purine antagonist and antiviral agent with the molecular formula C10H15N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 359HUE8FJC, chemically known as 6h-purin-6-one, 2-amino-1,9-dihydro-9-(4-hydroxy-3-(hydroxymethyl)butyl)- & human interferon-.gamma. but generally known as penciclovir, which bears US NIH Compound Identifier 4725. European Medicines Agency schedules Penciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09661MIG.

UNSPSC 51342307 Penciclovir, a Commodity code, does not reflect the pharmaceutical products state and local governments are actually purchasing under this classification. The recent opportunities posted under this code involve naloxone (an opioid antagonist) and antibiotic tablets (doxycycline and ciprofloxacin), not penciclovir antivirals. The mismatch suggests this code may be incorrectly applied to broader pharmaceutical stockpiling and emergency preparedness procurement, where state health departments and counties acquire critical medications for public health response, community health initiatives, and strategic national stockpile replenishment. When opportunities do post under this code, issuing bodies include state health departments (Illinois Department of Public Health) and county health authorities (Seminole County, Florida), typically procuring bulk quantities with long shelf-life requirements and multi-year supply contracts.

Geographic activity visible in the recent record spans Illinois and Florida, with procurement vehicles including both traditional competitive bidding (IFB) and cooperative purchasing consortia such as MMCAP Infuse. The Illinois Department of Public Health awarded a $2,999,999.11 multi-year pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 covering antibiotic supplies with delivery to state stockpiles. Seminole County, Florida issued an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for delivery to the Seminole County Community Health Building, with responses due July 26, 2026, on a two-year initial term with renewal options. Neither opportunity carried SBE, MBE, or VBE set-asides. Given the code's apparent misalignment with its nominal scope, prospecting under UNSPSC 51342307 carries execution risk—verify vendor qualification against the actual pharmaceutical products being purchased before committing resources.